



Article

Establishment of a Real-Time PCR Assay for the Detection of Devriesea agamarum in Lizards

Maria Brockmann ^{1,*}, Christoph Leineweber ¹, Tom Hellebuyck ², An Martel ², Frank Pasmans ², Michaela Gentil ¹, Elisabeth Müller ¹ and Rachel E. Marschang ¹

- Laboklin GmbH & Co. KG, Steubenstr. 4, 97688 Bad Kissingen, Germany
- Department of Pathobiology, Pharmacology and Zoological Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium
- * Correspondence: brockmann@laboklin.com

Simple Summary: Bacterial infections can play an important role in dermatitis in lizards. The bacterial species *Devriesea* (*D*.) *agamarum* is a known cause of dermatitis, cheilitis and even fatal disease in lizards. Disease has most often been reported in *Uromastyx* species, but other lizards may also be affected. However, some are asymptomatic carriers, increasing the risk of spreading *D. agamarum*. Usually, *D. agamarum* is detected with culture-based methods. It was the aim of this study to establish a real-time PCR assay to expand diagnostic options in routine diagnostics. The presented assay is able to detect *D. agamarum* in clinical samples, decreasing laboratory turn-around time in comparison to conventional culture-based detection methods. This enables a fast therapeutic approach for affected animals and decreases the risk of spread.

Abstract: (1) Background: *Devriesea* (*D.*) *agamarum* is a potential cause of dermatitis and cheilitis in lizards. The aim of this study was to establish a real-time PCR assay for the detection of *D. agamarum*. (2) Methods: Primers and probe were selected targeting the 16S rRNA gene, using sequences of 16S rRNA genes of *D. agamarum* as well as of other bacterial species derived from GenBank. The PCR assay was tested with 14 positive controls of different *D. agamarum* cultures as well as with 34 negative controls of various non-*D. agamarum* bacterial cultures. Additionally, samples of 38 lizards, mostly *Uromastyx* spp. and *Pogona* spp., submitted to a commercial veterinary laboratory were tested for the presence of *D. agamarum* using the established protocol. (3) Results: Concentrations of as low as 2×10^4 colonies per mL were detectable using dilutions of bacterial cell culture (corresponding to approximately 200 CFU per PCR). The assay resulted in an intraassay percent of coefficient of variation (CV) of 1.31% and an interassay CV of 1.80%. (4) Conclusions: The presented assay is able to detect *D. agamarum* in clinical samples, decreasing laboratory turn-around time in comparison to conventional culture-based detection methods.

Keywords: *Devriesea agamarum*; polymerase chain reaction; *Uromastyx* sp.; *Pogona vitticeps*; bearded dragon; lizard; reptile; cheilitis; dermatitis

lished: 28 February 2023 1. Introduction

Devriesea (D.) agamarum is a bacterial species known to cause dermatitis and cheilitis in lizards. Disease has most often been described in *Uromastyx* spp. [1–5]. However, D. agamarum can also infect other lizards [6,7]. It has been reported in captive [8,9] as well as in free-ranging lizards [7]. Clinical signs of disease generally include dermatitis or cheilitis, often described with a yellow crusty appearance [10]. Disease outbreaks with extensive mortality have also been reported, especially if lizards developed septicaemia. [7,11]. Bearded dragons have been described to asymptomatically carry D. agamarum in their oral cavities [2,3]. Treatment of affected animals usually includes debridement of dermal lesions



Citation: Brockmann, M.; Leineweber, C.; Hellebuyck, T.; Martel, A.; Pasmans, F.; Gentil, M.; Müller, E.; Marschang, R.E. Establishment of a Real-Time PCR Assay for the Detection of *Devriesea* agamarum in Lizards. Animals 2023, 13, 881. https://doi.org/10.3390/ ani13050881

Academic Editor: Simone Taddei

Received: 18 January 2023 Revised: 20 February 2023 Accepted: 24 February 2023 Published: 28 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Animals 2023, 13, 881 2 of 12

> and systemic use of antibiotics—especially cephalosporines are considered effective [4,12] and may also require disinfection of the enclosure [13]. Autovaccines have also been discussed as a treatment method [14].

> Therefore, a fast and reliable diagnostic approach is an important consideration, both in clinical disease with suspected D. agamarum infection and in entry controls. D. agamarum is relatively easily cultured at 37 °C but also grows at temperatures of 25-42 °C on Columbia agar with 5% sheep blood [11]. Diagnosis can, however, be complicated in laboratories with limited experience with this pathogen. Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS), one of the most frequently used standard techniques for the identification of bacteria in routine laboratory diagnostics, may not (yet) be able to identify *D. agamarum* when working with standardized databases [15]. However, this issue is likely to be overcome as databases expand. Currently, laboratories can improve D. agamarum identification by implementing and expanding their own MALDI-TOF MS databases or using 16S rRNA gene sequencing to identify cultured but unidentified isolates. Another option would be a specific PCR assay for D. agamarum, which might prove especially valuable if other infectious agents, such as viral or fungal pathogens, are also suspected, allowing concurrent testing from the same sample. The aim of this study was, therefore, to develop a PCR assay for the detection of *D. agamarum*.

2. Materials and Methods

2.1. Bacterial Isolates Used to Establish the qPCR

In total, 14 *D. agamarum* isolates were used in this study as positive controls.

Three D. agamarum isolates (GenBank accession numbers: MT664091-93) were obtained from routine diagnostic submissions at Laboklin GmbH & Co. KG (Bad Kissingen Germany) in 2019 [15], while 11 were isolated between 2005 and 2009 at the Faculty of Veterinary Medicine, Ghent University (Table 1). Non-D. agamarum isolates (n = 34) were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Some were included in order to determine the ability of the assay to exclude a broad spectrum of different bacterial species. Others, like Brachybacterium sp. or Dermabacter sp., were included as their sequences were described to be highly similar to D. agamarum [11] (Table 2). These 34 isolates served to determine the specificity of the PCR.

No. **Isolate** Host Sample Material Laboratory 1 MT664091.1/0219 Bf Brachylophus fasciatus Swab (skin) 2 MT664092.1/0919 Ur *Uromastyx* sp. Swab (skin)

Laboklin GmbH & Co. KG, Germany Laboklin GmbH & Co. KG, Germany 3 MT664093.1/0319 Ur Swab (skin) Laboklin GmbH & Co. KG, Germany *Uromastyx* sp. Faculty of Veterinary Medicine, 4 IMP2 vacc Swab (dermatitis), liver Agama impalearis Ghent University Swab (dermatitis, Faculty of Veterinary Medicine, 5 30.7 *Uromastyx dispar* cheilitis) Ghent University Swab (dermal Faculty of Veterinary Medicine, 34.1 6 Uromastyx acanthinura abscess) Ghent University Faculty of Veterinary Medicine, 7 23 Pogona vitticeps Swab (oral cavity) Ghent University Faculty of Veterinary Medicine, 8 24 Pogona vitticeps Swab (oral cavity) **Ghent University** Faculty of Veterinary Medicine, 9 25 Pogona vitticeps Swab (oral cavity) Ghent University Faculty of Veterinary Medicine, 10 26 *Crotaphytus collaris* Swab (dermatitis) Ghent University

Table 1. *Devriesea agamarum* isolates used to establish the PCR.

Animals **2023**, 13, 881 3 of 12

 Table 1. Cont.

No.	Isolate Host		Sample Material	Laboratory
11	28	Eublepharis macularius	Swab (oral cavity)	Faculty of Veterinary Medicine, Ghent University
12	30b	Ctenonotus gingivus	Swab (cloaca)	Faculty of Veterinary Medicine, Ghent University
13	4d	Iguana delicatissima	Swab (dermal abscess)	Faculty of Veterinary Medicine, Ghent University
14	L26	Pogona vitticeps	Swab (oral cavity)	Faculty of Veterinary Medicine, Ghent University

Table 2. Bacterial species used as negative controls to determine the specificity of the PCR.

No.	Bacterial Species	DSMZ Number	Original Depositor (Acc. to DSMZ)
1	Acinetobacter baumannii	DSM 30007	J.V. Cook
2	Bacillus atrophaeus	DSM 675	E. McCoy
3	Cytobacillus firmus	DSM 359	G. Bredemann
4	Brachybacterium faecium	DSM 4810	H.E. Schefferle
5	Dermabacter hominis	DSM 30958	C. Moissl-Eichinger
6	Enterococcus faecalis	DSM 2570	Kaiser-Permanente
7	Enterococcus faecium	DSM 20477	A. Grumbach
8	Enterococcus faecium	DSM 2146	J.M. Skerman (Streptococcus faecalis)
9	Escherichia coli	DSM 1103	F. Schoenknecht
10	Escherichia coli	DSM 1576	G.C. Crooks
11	Flavobacterium psychrophilum	DSM 21280	JF. Bernardet
12	Klebsiella oxytoca	DSM 5175	R. Hugh
13	Klebsiella pneumoniae	DSM 26371	H. Dalton
14	Klebsiella pneumoniae	DSM 30104	CDC, Atlanta; 298-53
15	Listeria monocytogenes	DSM 19094	H. Seeliger
16	Mycobacterium phlei	DSM 750	IPH
17	Nocardia nova	DSM 44481	N. F. Conant
18	Proteus hauseri	DSM 30118	K.B. Lehmann
19	Proteus mirabilis	DSM 4479	CDC PR 14
20	Pseudomonas aeruginosa	DSM 1128	C.P. Hegarty
21	Pseudomonas aeruginosa	DSM 1117	A. Madeiros
22	Salmonella enterica	DSM 19587	CDC
23	Salmonella enterica	DSM 17420	CDC
24	Staphylococcus aureus	DSM 2569	E.H. Gerlach
25	Staphylococcus aureus	DSM 1104	F. Schoenknecht
26	Staphylococcus aureus	DSM 46320	W. Witte
27	Staphylococcus aureus	DSM 799	AMC
28	Streptococcus dysgalactiae	DSM 20662	T.M. Higgs
29	Staphylococcus epidermidis	DSM 1798	FDA
30	Streptococcus equi ssp. equi	DSM 20561	R.E.O. Williams
31	Staphylococcus felis	DSM 7377	S. Igimi
32	Staphylococcus intermedius	DSM 20373	V. Hajek
33	Streptococcus pyogenes	DSM 11728	E. Mortimer
34	Yersinia enterocolitica	DSM 4780	J.M. Coffey

Animals 2023, 13, 881 4 of 12

2.2. DNA Preparation

Pure cultures of each strain were incubated in 750 μ L lysis buffer (MagNA Pure DNA Tissue Lysis Buffer, Roche, Mannheim, Germany) and 75 μ L proteinase K (proteinase K, lyophilisiert, \geq 30 U/mg, Carl Roth GmbH & Co KG, Karlsruhe, Germany) for one hour at 65 °C. From this, 200 μ L were utilized for automated nucleic acid (NA) extraction using the MagNA Pure 96 DNA and Viral NA Small Volume Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. The resulting NAs were eluted in a volume of 100 μ L. The isolated NAs were kept at -18 °C until the PCR tests were performed. The DNA used for the dilution series was extracted manually using the QIAamp[®] DNA MicroKit (50) (Qiagen, Hilden, Germany), and the DNA concentration was measured with a spectrophotometer (NanoDrop 2000, Thermo Fisher Scientific, Inc., Wilmington, NC, USA).

2.3. Design of Primers and Oligonucleotide Probe, PCR Protocol and Optimisation of Annealing Temperature

The 16S rRNA gene was selected as the target region based on the availability of sequence data from a variety of isolates. Sequences of *D. agamarum* (NZ_LN849456.1, LN849456.1, NR_044368.1, EU009865.1, KF647330.1) were retrieved from GenBank, and multiple sequence alignment was performed with other sequences of different bacterial species (e.g., *Agromyces* species, *Arthobacter* species, *Brachybacterium* species, *Dermabacter* species, *Pseudomonas* species) using MUSCLE (https://www.ebi.ac.uk/Tools/msa/muscle/last accessed on 20 February 2023). The primers and probe were designed using primer3 (https://primer3.ut.ee/last accessed on 20 February 2023).

Reactions included 1.0 μ L of each primer (10 μ M), 1.0 μ L of the probe (2 μ M), 4.0 μ L DNA Process Control Detection Kit qPCR Reaction Mix and 5.0 μ L template DNA in a total volume of 20.0 μ L. Amplification was performed with a LightCycler 96 (Roche, Mannheim, Germany) in a 96-well format.

The following protocol was used: Preincubation at 95 °C for 30 s followed by 40 cycles of two-step-amplification (95 °C for 5 s and 60 °C for 30 s). PCR-grade water (Roche, Mannheim, Germany) served as a negative control. While all other bacterial samples were negative, *Dermabacter hominis* produced positive PCR results at an annealing temperature of 60 °C (Figure 1). Therefore, DNA of *Dermabacter hominis* (DSM 30958) from the DSMZ as well as DNA of *D. agamarum* (GenBank Accession number: MT664092.1/0919Ur) [15], was tested in duplicate with different annealing temperatures (protocol 1: 65.0 °C, protocol 2: 66.0 °C, protocol 3: 67.0 °C) using a LightCycler 96 (Roche, Mannheim, Germany).




Figure 1. Two-step amplification carried out at 60 °C: All *Devriesea agamarum* isolates tested resulted in positive signals with CT values ranging from 12.61 to 18.54. *Dermabacter hominis* (blue curve) also gave a positive signal with a CT value of 26.29.

2.4. Determination of Specificity at 66 $^{\circ}\text{C}$ and of Repeatability and Sensitivity of the Assay

Various non-*D. agamarum* bacterial species (Table 2) were tested in duplicate for positive reactions at 66 °C. The following protocol was used: Preincubation at 95 °C for 30 s followed by 40 cycles of two-step-amplification (95 °C for 5 s and 66 °C for 30 s). PCR-grade water (Roche, Mannheim, Germany) served as a negative control. DNA of 14 *D. agamarum* isolates (Table 1) was also tested.

Animals 2023, 13, 881 5 of 12

To assess the intraassay repeatability of the PCR, standard deviations were calculated for 10-fold serial dilutions in triplicate on a single plate. For the interassay reproducibility, standard deviations were calculated for a 10-fold serial dilution series which was amplified three times daily for two days. The standard deviations of the CT values were used to calculate the percent of coefficient of variation (CV%).

Detection limit for bacterial cell dilutions: In order to determine the sensitivity of the assay, a culture of D. agamarum (isolate MT664091.1/0219Bf) was used, starting with a dilution (D0) of 0.5 McFarland (1.5×10^8 per mL). This suspension (D0) was 10-fold serially diluted (D1–D10) in duplicate, and 1 mL of each dilution was inoculated onto Columbia agar with defibrinated sheep blood (Becton Dickinson GmbH, Heidelberg, Germany/Oxoid GmbH, Wesel, Germany), incubated at 36 °C and checked for growth after 30 h. Colony forming units (CFU) were counted if the result was expected to be between 0 and 300 CFU. These results were then used to determine the limit of detection of the assay. DNA was extracted from 200 μ L of each dilution (D1–D10) as described above, and PCR was carried out in duplicate. The detection of $Dermabacter\ hominis$ (DSM 30958) was quantified in the same way.

Detection limit for DNA from pure culture: To evaluate the assay's sensitivity, PCR was carried out in triplicate using serial 10-fold dilutions of DNA prepared from colonies of *D. agamarum* (isolate MT664091.1/0219Bf).

Spiked-in matrix: The assay was also evaluated using a spiked-in matrix (D. agamarum-negative-tested lizard skin with a known concentration of target DNA). For these assays, $10~\mu L$ of the above-described dilutions D0 to D6 were inoculated onto D. agamarum-negative-tested lizard skin. The skin was incubated in $500~\mu L$ lysis buffer, and $50~\mu L$ proteinase K and NA were extracted from $200~\mu L$ of this suspension as described above and eluted in a total volume of $100~\mu L$ NA. The PCR was carried out in duplicate as described above.

2.5. Testing of Samples Submitted to a Commercial Veterinary Laboratory

Clinical samples from lizards for which appropriate material (skin, crusts, dry swab) was submitted to a commercial veterinary laboratory between March 2022 and December 2022 and for which the submitting veterinarian indicated an interest in D. agamarum diagnostics were tested using the established protocol to evaluate the PCR for use with clinical samples. Some of the samples were derived from animals showing clinical signs, others from asymptomatic animals tested in the context of a health check—often when *D*. agamarum had been isolated from animals in the group previously. If suitable material was available (skin or swab in a transport medium), bacteriology was performed (as previously described [15]). Identification of isolates was based on growth characteristics on agar plates (Columbia Agar with defibrinated sheep blood and Endo Agar, Becton Dickinson GmbH, Heidelberg, Germany), biochemical parameters and MALDI-TOF MS. In doubt, colonies were also re-checked via PCR. If the results of the bacteriological culture were available, the results of the PCR and culture would be compared. Samples were considered PCR positive if the cycle threshold (CT) was <35.0 and equivocal if the CT was ≥35.0 , but a signal was obtained. If swabs of different origins regarding the localisation (e.g., dermal and oral) of the same animal were received, all samples were tested separately. Amplicons from positive samples were sequenced (ABI PRISM 3130 XL Genetic Analyser, Applied Biosystems, Foster City, CA, USA) and sequences were analysed by BLAST (https: //blast.ncbi.nlm.nih.gov/Blast.cgi, last accessed on 20 February 2023).

3. Results

3.1. Development of the PCR

The selected primer and probe sequences (Eurofins MWG Operon, Ebersberg, Germany) are shown in Table 3. The product size was expected to be 246 base pairs.

Animals 2023, 13, 881 6 of 12

Forward Primer Devag16_For	GATGACTGCAGAGATGTGGTG
Reverse Primer Devag16_Rev	TTTGTACCGGCCATTGTAGCAT
Oligonucleotide probe FAM BHQ1	CATGTTGCCAGCACTTCGG

Table 3. Primers and probe used in the PCR for detection of *Devriesea agamarum*.

Optimisation of annealing temperature was performed using three protocols with different annealing temperatures. In protocol 1 (65 °C), *D. agamarum* DNA was detected with CT values of 14.58 and 16.49 and *Dermabacter hominis* with CT values of 29.43 and 29.62. In protocol 2 (66 °C), *D. agamarum* DNA was detected with CT values of 16.22 and 16.14, and *Dermabacter hominis* showed values of 34.28 and 35.19. In protocol 3 (67 °C), *D. agamarum* was detected with CT values of 15.57 and 16.57, while *Dermabacter hominis* was not detected. Therefore, an annealing temperature of 66 °C was chosen for all further analyses as it was considered sufficient to discriminate between pure cultures of *D. agamarum* and *Dermabacter hominis* DNA without losing sensitivity for the detection of *D. agamarum*.

3.2. Specificity, Repeatability and Sensitivity of the Assay

Specificity of the assay using the protocol with 66 °C as an annealing temperature was determined using 14 *D. agamarum* isolates (Table 1) and 34 non-*D. agamarum* bacterial isolates (Table 2) in duplicate.

No signal was obtained from any bacterial DNA from isolates other than D. agamarum except for $Dermabacter\ hominis$. The CT value obtained using the DNA from pure cultures of $Dermabacter\ hominis$ were high (34.55 and 34.48) in comparison to those reached using DNA from D. agamarum (12.08–18.14) but still below the threshold set for clinical samples. As these are the results for DNA extracted from pure culture, 66 °C was considered sufficient for further testing of samples without prior cultivation as samples without prior cultivation are expected to yield a lower pathogen level. The intraassay CV was calculated to be 1.31%, while the interassay CV was 1.80%.

<u>Detection limit for bacterial cell dilutions</u>: A positive PCR signal was detected for *D. agamarum* dilutions D0–D4. An equivocal signal was detected for D5 and D6. In culture, D4 corresponded to 2×10^4 colonies per mL. Therefore, the assay sensitivity was 2×10^4 colonies per mL with dilutions of bacterial cell culture serving as a template. This corresponds to approximately 200 CFU per PCR. For the serially diluted culture of *Dermabacter hominis*, no positive PCR signals were observed. Two dilutions (D0 and D1) resulted in equivocal CT values, with D0 being set to 0.5 McFarland (1.5 \times 10⁸ per mL).

Detection limit for DNA from pure culture: The DNA concentration was determined to be $\overline{42.5}$ ng/µL (A260/A280: 1.94). *D. agamarum* DNA was detectable in dilutions up to 1:10⁵. Therefore, DNA concentrations of as low as 425 fg/µL were detectable in the PCR.

Spiked-in matrix: Spiked-in matrixes produced clearly positive results up to skin spiked with 10 μ L of D2 with D2 corresponding to 2 \times 10⁶ colonies per mL (approximately 360 CFU per PCR considering dilution during sample preparation).

3.3. Testing of Clinical Samples

In order to test the use of the developed PCR for clinical samples, a total of 48 samples from 38 lizards were tested for the presence of *D. agamarum* (Table 4). The samples were derived from several species, mostly agamids (*Pogona* spp. and *Uromastyx* spp.), and were of different origins (zoological collection, animal rescue centre, private owner) from Germany and the Netherlands. Some of these animals were asymptomatic and were tested in the context of a health check. Others showed clinical signs such as skin lesions, hyperkeratosis or stomatitis (Table 4). Samples were mostly derived from the oral cavity or skin/crusts. Of the 38 animals tested, *D. agamarum* was detected by PCR in 16 animals (42.10%). A further five animals (13.16%) were considered to have equivocal results, and 17 animals (44.74%) were negative for *D. agamarum*. One animal (animal 3) that tested negative proved to be infected with a fungus of the family Onygenaceae. A bacteriological

Animals **2023**, 13, 881 7 of 12

examination was performed for 33 of the 38 animals, but *D. agamarum* was not cultured. However, in most of these cases, various other bacterial species (Table 4) were cultured when bacteriology was performed.

Table 4. Results of bacteriological culture and *Devriesea agamarum* PCR of clinical samples from 38 lizards.

Animal No.	Species	Clinical Signs and History and Additional Information	Country of Origin	Time from Sampling to Sample Preparation:	Sample Material	Bacterial Culture	PCR Result
1	<i>Uromastyx</i> sp.	Suspicious skin lesion Same wildlife park as animal 2	NL	unknown	Skin	N.D.	Positive (CT 23.71)
2	<i>Uromastyx</i> sp.	Suspected lesions/ dermatitis Same wildlife park as animal 1	NL	unknown	Swabs (skin)	N.D.	Positive (CT 30.53)
3	Pogona sp.	Black discoloration of the scales after shedding, especially on the tail.	NL	5d	Skin Swab (skin)	+ Glutamibacter - creatinolyticus + Micrococcus sp. + aerobic spore-forming bacteria	Negative Negative
4	<i>Uromastyx</i> sp.	Partner to animal 5	NL	2d	Swab (oral mucosa)	++ Pantoea agglomerans ++ Pseudomonas aeruginosa ++ aerobic spore-forming bacteria	Positive (CT 28.47)
5	<i>Uromastyx</i> sp.	Partner to animal 4	NL	2d	Swab (oral mucosa)	++ Exiguobacterium mexicanum ++ Kluyvera intermedia ++ Pseudomonas chlororaphis ++ aerobic spore-forming bacteria	Negative
6	<i>Uromastyx</i> sp.	Reported to have been treated with antibiotics	NL	2d	Swab (oral mucosa)	++ Acinetobacter variabilis +++ Arthrobacter globiformis + Bacillus cereus	Positive (CT 28.44)
7	Pogona vitticeps	No clinical signs	DE	1d	Swab (oral mucosa)	++ Proteus mirabilis	Positive (CT 33.17)
8	Pogona vitticeps	No clinical signs	DE	1d	Swab (oral mucosa)	+++ Enterobacter cloacae + Pseudomonas aeruginosa	Equivocal (CT 35.71)
9	Pogona vitticeps	No clinical signs Partner to animal 10 Confiscated	DE	1d	Swab (oral mucosa)	++ Bordetella hinzii	Negative
10	Pogona vitticeps	No clinical signs Partner to animal 9 Confiscated	DE	1d	Swab (oral mucosa)	+ Bordetella hinzii + Peribacillus muralis ++ Enterococcus faecalis + Pantoea agglomerans	Negative
11	Pogona vitticeps	No clinical signs Abandoned	DE	1d	Swab (oral mucosa)	++ Morganella morganii ++ Klebsiella oxytoca	Positive (CT 27.56)
12	Pogona vitticeps	No clinical signs Abandoned	DE	1d	Swab (oral mucosa)	++ Klebsiella oxytoca + Proteus mirabilis	Negative
13	Pogona henrylawsoni	No clinical signs Abandoned juvenile same enclosure as animals 14 and 15	DE	unknown	Swab (oral mucosa)	+ Aeromonas hydrophila (+) aerobic spore-forming bacteria	Negative
14	Pogona henrylawsoni	No clinical signs Abandoned juvenile same enclosure as animals 13 and 15	DE	unknown	Swab (oral mucosa)	++ Proteus mirabilis (+) aerobic spore-forming bacteria	Negative
15	Pogona henrylawsoni	No clinical signs Abandoned juvenile same enclosure as animals 13 and 14	DE	unknown	Swab (oral mucosa)	+ Aeromonas hydrophila (+) alpha-hemolytic streptococci	Negative

Animals **2023**, 13, 881 8 of 12

 Table 4. Cont.

Animal No.	Species	Clinical Signs and History and Additional Information	Country of Origin	Time from Sampling to Sample Preparation:	Sample Material	Bacterial Culture	PCR Result
16	Pogona vitticeps	No clinical signs	DE	unknown	Swab (oral mucosa)	+ Aeromonas hydrophila + Pseudomonas aeruginosa (+) aerobic spore-forming bacteria	Positive (CT 27.20)
17	Pogona vitticeps	No clinical signs	DE	unknown	Swab (oral mucosa)	+++ Klebsiella oxytoca	Equivocal (CT 35.26)
18	Pogona vitticeps	No clinical signs	DE	unknown	Swab (oral mucosa)	++ Klebsiella oxytoca	Equivocal (CT 35.07)
19	Scincidae	Unknown	DE	2d	Skin	N.D.	Negative
20	Iguanidae	Hyperkeratosis (dorsal)	DE	2d	Skin	N.D.	Negative
21	<i>Uromastyx</i> sp.	Skin lesion	DE	2d	Skin	N.D.	Positive (CT 21.34)
				unknown	Swab (outer skin of the mouth)	+ Pseudomonas aeruginosa + Serratia marcescens	Positive (CT 28.45)
22	<i>Uromastyx</i> sp.	Skin lesion Animals 22, 23 and	DE		Swab (oral mucosa)	+ Pseudomonas aeruginosa + Serratia marcescens	Positive (CT 34.89)
		24 kept in the same enclosure			Skin	N.D.	Positive (CT 31.56)
					Swab (skin)	N.D.	Positive (CT 30.88)
		Skin lesion Animals 22, 23 and 24 kept in the same enclosure			Swab (outer skin of the mouth)	+ Enterobacter cloacae	Positive (CT 32.20)
23	<i>Uromastyx</i> sp.		DE	unknown	Swab (oral mucosa)	+ Enterobacter cloacae	Positive (CT 32.06)
	7 1				Skin	N.D.	Positive (CT 31.97)
					Swab (Skin)	N.D.	Positive (CT 34.05)
				unknown -	Swab (outer skin of the mouth)	+ Pseudomonas synxantha	Equivocal (CT 35.24)
24	<i>Uromastyx</i> sp.	Skin lesion Animals 22, 23 and 24 kept in the same enclosure	DE		Swab (oral mucosa)	+ Pantoea agglomerans	Negative
					Skin	N.D.	Positive (CT 33.84)
					Swab (Skin)	N.D.	Equivocal (CT 35.75)
		Multiple animals			Swab (skin)	N.D.	Negative
25	Corucia zebrata	with minimal to moderate stomatitis	NL	2d	Skin	+++ Pseudomonas aeruginosa	Negative
26	Chlamydosaurus kingii	No clinical signs Kept with animal 27	DE	5d	Swab (oral mucosa)	+ Proteus mirabilis ++ Serratia marcescens	Negative
27	Chlamydosaurus kingii	No clinical signs Kept with animal 26	DE	5d	Swab (oral mucosa)	+ Klebsiella oxytoca + Stenotrophomonas maltophilia + aerobic spore-forming bacteria	Negative
28	Laemanctus serratus	No clinical signs Kept with animals 29 and 30	DE	5d	Swab (oral mucosa)	+ Klebsiella oxytoca + Morganella morganii	Positive (CT 31.20)
29	Laemanctus serratus	No clinical signs Kept with animals 28 and 30	DE	5d	Swab (oral mucosa)	+ Deinococcus proteolyticus + Morganella morganii + Serratia marcescens	Positive (CT 34.35)
30	Laemanctus serratus	No clinical signs Kept with animals 28 and 29	DE	5d	Swab (oral mucosa)	+ Morganella morganii + Proteus mirabilis	Positive (CT 29.10)

Animals 2023, 13, 881 9 of 12

Table 4. Cont.

Animal No.	Species	Clinical Signs and History and Additional Information	Country of Origin	Time from Sampling to Sample Preparation:	Sample Material	Bacterial Culture	PCR Result
31	Laudakia stellio picea	No clinical signs Kept with animal 32	DE	5d	Swab (oral mucosa)	(+) aerobic spore-forming bacteria	Equivocal (CT 35.80)
32	Laudakia stellio picea	No clinical signs Kept with animal 31	DE	5d	Swab (oral mucosa)	+ Pseudomonas sp. + Serratia marcescens + aerobic spore-forming bacteria	Equivocal (CT 36.87)
33	Pogona vitticeps	No clinical signs Kept with animal 34	DE	5d	Swab (oral mucosa)	(+) Staphylococcus epidermidis	Positive (CT 34.07)
34	Pogona vitticeps	No clinical signs Kept with animal 33	DE	5d	Swab (oral mucosa)	+ Staphylococcus aureus (+) aerobic spore-forming bacteria	Positive (CT 32.61)
35	Pogona vitticeps	Juvenile No clinical signs Kept with animals 36, 37 and 38	DE	5d	Swab (oral mucosa)	(+) aerobic spore-forming bacteria	Negative
36	Pogona vitticeps	Juvenile No clinical signs Kept with animals 35, 37 and 38	DE	5d	Swab (oral mucosa)	+ Achromobacter xylosoxidans	Negative
37	Pogona vitticeps	Juvenile No clinical signs Kept with animals 35, 36 and 38	DE	5d	Swab (oral mucosa)	+ <i>Serratia marcescens</i> (+) aerobic spore-forming bacteria	Negative
38	Pogona vitticeps	Juvenile No clinical signs Kept with animals 35, 36 and 37	DE	5d	Swab (oral mucosa)	+ Proteus mirabilis	Negative

Legend: N.D. = not done, d = days, DE = Germany, NL = the Netherlands.

4. Discussion

D. agamarum is an important pathogen causing skin lesions and, in some cases, systemic disease in lizards. Depending on the species, some animals can be inapparent carriers, while others may develop severe diseases. Diagnosis of the causative agent is therefore important in order to facilitate treatment as well as to prevent the spread of disease. Since animals may suffer when untreated and the risks of spreading increase with time, a fast diagnostic approach is important. The detection of *D. agamarum* is commonly achieved via culture, followed in some cases by 16S rRNA gene sequencing [11,16].

The PCR developed in this study provides a time-saving tool compared to culture and bacterial identification. Detection of D. agamarum and concurrent bacteriological examination was performed in 33 of the 38 animals, resulting in 13 of 33 clearly PCRpositive animals but no culture-positives. D. agamarum is expected to be abundantly present in symptomatic animals. Culturing of D. agamarum is not considered difficult and has been successfully performed in this laboratory before [15]. However, a successful culture depends on the quality of the submitted samples. Appropriate samples include affected tissue below hyperkeratotic crusts or inside of the crusts as well as organs in septicaemic lizards and subcutaneous granulomas. In asymptomatic animals as well as in symptomatic animals, isolation from the oral cavity, gastrointestinal tract or healthy skin may be challenging. D. agamarum was cultured in the laboratory in which the study was performed during the study period, but these samples were excluded from the study as no suitable material for concurrent PCR testing (e.g., dry swab, skin) was available. In this study, six animals (1, 2, 21 and 22-24) were known to have been symptomatic and had positive PCR results. Bacteriological culture was performed in three of these animals (22-24). In animal 24, a positive PCR result was only obtained from the skin sample, which was not tested by bacteriological culture. Animal 6 might have been symptomatic (no information was received, but due to the reported previous treatment, it seemed likely). It was treated with antibiotics prior to sampling, which might have influenced the bacteriology results. Possible reasons for the failure of culturing D. agamarum out of positive

Animals 2023, 13, 881 10 of 12

clinical samples in this study include previous antibiotic treatment, incorrect sampling techniques, contamination with (oral) microbiota, increased transport time, inappropriate transport conditions or overgrowth by other bacteria. The latter is especially important as in the presented cases, no selective media for gram-positive bacteria were used, and various different bacterial species are expected to be present on the skin [17,18].

PCR analysis is useful if the performance of bacterial culture is difficult, e.g., due to previous treatment with antibiotics, inadequate preanalytical conditions (such as increased or decreased temperature, increased transport time, inadequate transport medium), or in cases in which overgrowth by other bacteria make detection challenging or impossible. The detection of *D. agamarum* via PCR can also simplify concurrent PCR testing for other known pathogens, e.g., viral or fungal pathogens known to cause dermatitis [19,20], since the same extracted nucleic acids can be used. In general, PCR is advantageous when culturable samples are unavailable, for example, when older samples are tested or stored DNA is examined. However, bacterial DNA can persist in the environment [21], and *D. agamarum* has been shown to survive for several months in the environment, depending on the conditions [13]. A PCR could therefore detect bacteria even in cases in which these were not responsible for clinical signs or in which no replication-competent bacteria were present.

The PCR developed here was not 100% specific. Pure cultures of Dermabacter hominis did result in a weak positive signal. However, if diluted, only equivocal results were observed. Dermabacter hominis is genetically closely related to D. agamarum [2,11,22]. Dermabacter hominis is associated with the human microbiome [23]. It is occasionally described in human clinical samples such as abscesses or blood cultures [24–26] but is usually found to be of minor clinical significance [27]. So far, its clinical importance in reptiles is very unclear. Contamination during sampling or sample preparation should be considered a possible option leading to false equivocal results. However, clinical samples are expected to yield less bacterial DNA, making false equivocal results less likely. The 16S rRNA gene is known to be highly conserved between bacterial species, which makes it a useful target if the aim is to identify different bacterial species. It is a commonly used target for bacterial detection, and therefore a large amount of sequence data is available for a wide range of bacterial species. However, it may not be ideal for differentiating closely related bacteria. Currently, the availability of sequence data for *D. agamarum* other than the 16S rRNA gene is limited, but in the future, other targets may prove to be better options. In the meantime, especially equivocal CT values should be evaluated with caution in the face of clinical signs, sampling and sample preparation, and ideally, retesting is recommended. Possibly, skin samples might prove more useful than swabs as they yielded lower CT values in two of the three animals for which both sample types were available, but this might be highly dependent on the sampling method.

The PCR protocol developed in this study proved helpful for the detection of *D. agamarum* in clinical samples. *D. agamarum* was detected in oral swabs from clinically healthy *Pogona* species and serrated casquehead iguana (*Laemanctus serratus*), while the results in which equivocal results were obtained were also from clinically healthy *Pogona* species as well as from clinically healthy black hardun (*Laudakia stellio picea*). *Pogona* species have previously been shown to be possible inapparent carriers of *D. agamarum* and a possible source of infection for more sensitive species [2,3].

Therefore, this PCR protocol may not only be useful for clinical cases but also as a screening tool. However, the number of tested samples is still small, and testing of larger sample numbers is necessary in order to confirm the usefulness of this method for clinical practice.

5. Conclusions

A real-time PCR was developed that is able to detect *D. agamarum* in clinical samples. The assay provides a fast method for the detection of this important pathogen of lizards but should be evaluated with further samples in the clinical context.

Animals 2023, 13, 881 11 of 12

Author Contributions: Conceptualization, M.B., E.M. and R.E.M.; Data curation, M.B., C.L. and R.E.M.; Formal analysis, M.B.; Methodology, M.B., M.G. and R.E.M.; Resources, M.B., C.L., T.H., A.M. and F.P.; Supervision, R.E.M.; Validation, M.B., M.G. and R.E.M.; Visualization, M.B.; Writing—original draft, M.B.; Writing—review & editing, C.L., T.H., A.M., F.P., M.G. and R.E.M. All authors have read and agreed to the published version of the manuscript.

Funding: The research received support in the form of salaries for authors [M.B., C.L., M.G., R.E.M.] from Laboklin GmbH & CO KG, a veterinary laboratory offering diagnostic services, including bacteriological and molecular biological examinations. The author E.M. is the head of the funding company.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Conflicts of Interest: Laboklin GmbH & Co. KG is a veterinary laboratory offering diagnostic services, including bacteriological and molecular biological examinations. This does not alter our adherence to sharing data and materials.

References

- 1. Haesendonck, R.; van Nieuwerburgh, F.; Haesebrouck, F.; Deforce, D.; Pasmans, F.; Martel, A. Genome Sequence of *Devriesea agamarum*, isolated from agamid lizards with dermatitis. *Genome Announc.* **2015**, *3*, e00949-15. [CrossRef] [PubMed]
- 2. Hellebuyck, T.; Martel, A.; Chiers, K.; Haesebrouck, F.; Pasmans, F. *Devriesea agamarum* causes dermatitis in bearded dragons (*Pogona vitticeps*). Vet. Microbiol. 2009, 134, 267–271. [CrossRef] [PubMed]
- 3. Devloo, R.; Martel, A.; Hellebuyck, T.; Vranckx, K.; Haesebrouck, F.; Pasmans, F. Bearded dragons (*Pogona vitticeps*) asymptomatically infected with *Devriesea agamarum* are a source of persistent clinical infection in captive colonies of dab lizards (*Uromastyx* sp.). *Vet. Microbiol.* **2011**, *150*, 297–301. [CrossRef] [PubMed]
- 4. Lukac, M.; Horvatek-Tomic, D.; Prukner-Radovcic, E. Findings of *Devriesea agamarum* associated infections in spiny-tailed lizards (*Uromastyx* sp.) in Croatia. *J. Zoo Wildl. Med.* **2013**, *44*, 430–434. [CrossRef]
- 5. Schmidt-Ukaj, S.; Hochleithner, M.; Richter, B.; Hochleithner, C.; Brandstetter, D.; Knotek, Z. A survey of diseases in captive bearded dragons: A retrospective study of 529 patients. *Vet. Med.* **2017**, *62*, 508–515. [CrossRef]
- 6. Rossier, C.; Hoby, S.; Wenker, C.; Brawand, S.G.; Thomann, A.; Brodard, I.; Jermann, T.; Posthaus, H. Devrieseasis in a plumed basilisk (*Basiliscus plumfrons*) and chinese water dragons (*Physignathus cocincinus*) in a zoologic collection. *J. Zoo Wildl. Med.* **2016**, 47, 280–285. [CrossRef]
- 7. Hellebuyck, T.; Questel, K.; Pasmans, F.; van Brantegem, L.; Philip, P.; Martel, A. A virulent clone of *Devriesea agamarum* affects endangered Lesser Antillean iguanas (*Iguana delicatissima*). *Sci. Rep.* **2017**, *7*, 12491. [CrossRef]
- 8. Schmidt-Ukaj, S.; Loncaric, I.; Klang, A.; Spergser, J.; Häbich, A.-C.; Knotek, Z. Infection with *Devriesea agamarum* and *Chrysosporium guarroi* in an inland bearded dragon (*Pogona vitticeps*). *Vet. Dermatol.* **2014**, 25, 555–558, e97. [CrossRef]
- 9. Gallego, M.; Juan-Sallés, C.; Hellebuyck, T. *Devriesea agamarum* associated cheilitis in a North African spiny-tailed lizard (*Uromastyx acanthinura*) in Spain. *Open Vet. J.* **2018**, *8*, 224–228. [CrossRef]
- 10. Hedley, J.; Whitehead, M.L.; Munns, C.; Pellett, S.; Abou-Zahr, T.; Calvo Carrasco, D.; Wissink-Argilaga, N. Antibiotic stewardship for reptiles. *J. Small Anim. Pract.* **2021**, *62*, 829–839. [CrossRef]
- 11. Martel, A.; Pasmans, F.; Hellebuyck, T.; Haesebrouck, F.; Vandamme, P. *Devriesea agamarum* gen. nov., sp. nov., a novel actinobacterium associated with dermatitis and septicaemia in agamid lizards. *Int. J. Syst. Evol. Microbiol.* **2008**, *58*, 2206–2209. [CrossRef] [PubMed]
- 12. Hellebuyck, T.; Pasmans, F.; Haesebrouck, F.; Martel, A. Designing a successful antimicrobial treatment against *Devriesea agamarum* infections in lizards. *Vet. Microbiol.* **2009**, *139*, 189–192. [CrossRef] [PubMed]
- 13. Hellebuyck, T.; Pasmans, F.; Blooi, M.; Haesebrouck, F.; Martel, A. Prolonged environmental persistence requires efficient disinfection procedures to control *Devriesea agamarum*-associated disease in lizards. *Lett. Appl. Microbiol.* **2011**, 52, 28–32. [CrossRef] [PubMed]
- 14. Hellebuyck, T.; van Steendam, K.; Deforce, D.; Blooi, M.; van Nieuwerburgh, F.; Bullaert, E.; Ducatelle, R.; Haesebrouck, F.; Pasmans, F.; Martel, A. Autovaccination confers protection against *Devriesea agamarum* associated septicemia but not dermatitis in bearded dragons (*Pogona vitticeps*). *PLoS ONE* **2014**, *9*, e113084. [CrossRef] [PubMed]
- 15. Brockmann, M.; Aupperle-Lellbach, H.; Gentil, M.; Heusinger, A.; Müller, E.; Marschang, R.E.; Pees, M. Challenges in microbiological identification of aerobic bacteria isolated from the skin of reptiles. *PLoS ONE* **2020**, *15*, e0240085. [CrossRef] [PubMed]
- 16. Bauwens, L.; Vercammen, F.; Hendrickx, F.; Pasmans, F.; Martel, A. Prevalence of *Devriesea agamarum* in the lizard collection of The Royal Zoological Society of Antwerp. *J. Zoo Aquar. Res.* **2014**, 2, 88.

Animals 2023, 13, 881 12 of 12

17. Brockmann, M.; Aupperle-Lellbach, H.; Müller, E.; Heusinger, A.; Pees, M.; Marschang, R.E. Aerobes Keimspektrum und Resistenzlage bei Hautläsionen von Reptilien. *Tierarztl. Prax. Ausg. K Kleintiere. Heimtiere.* 2020, 48, 78–88. [CrossRef]

- 18. Pasmans, F.; Martel, A.; Jacobson, E.R. Bacterial Diseases of Reptiles. In *Infectious Diseases and Pathology of Reptiles: Color Atlas and Text*; Jacobson, E.R., Ed.; CRC Press: Boca Raton, FL, USA, 2021; pp. 705–794.
- 19. Marschang, R.E.; Origgi, F.C.; Stenglein, M.D.; Hyndman, T.H.; Wellehan, J.F.; Jacobson, E.R. Viruses and Viral Diseases of Reptiles. In *Infectious Diseases and Pathology of Reptiles: Color Atlas and Text*; Jacobson, E.R., Ed.; CRC Press: Boca Raton, FL, USA, 2021; pp. 575–703.
- 20. Paré, J.A.; Conley, K.J. Mycotic Diseases of Reptiles. In *Infectious Diseases and Pathology of Reptiles: Color Atlas and Text*; Jacobson, E.R., Ed.; CRC Press: Boca Raton, FL, USA, 2021; pp. 795–857.
- 21. Young, G.; Turner, S.; Davies, J.K.; Sundqvist, G.; Figdor, D. Bacterial DNA persists for extended periods after cell death. *J. Endod.* **2007**, 33, 1417–1420. [CrossRef]
- 22. Bayram, L.C.; Abay, S.; Saticioglu, İ.B.; Güvenc, T.; Ekebas, G.; Aydi, F. Panophthalmitis in a Gentoo Penguin (*Pygoscelis Papua*) from the Antarctic Peninsula: Evaluation of Microbiological and Histopathological Analysis Outcomes. *Res. Sq.* **2021**, Preprint. [CrossRef]
- 23. Swaney, M.H.; Nelsen, A.; Sandstrom, S.; Kalan, L.R. Sweat and sebum preferences of the human skin microbiota. *Microbiol. Spectr.* **2023**, *11*, e04180-22. [CrossRef]
- 24. Gómez-Garcés, J.L.; Oteo, J.; García, G.; Aracil, B.; Alós, J.I.; Funke, G. Bacteremia by *Dermabacter hominis*, a rare pathogen. *J. Clin. Microbiol.* **2001**, 39, 2356–2357. [CrossRef] [PubMed]
- 25. Lee, H.-J.; Cho, C.-H.; Kwon, M.-J.; Nam, M.-H.; Lee, K.-N.; Lee, C.-K. A Patient with Fatal Septicemia Caused by a Rare Pathogen *Dermabacter Hominis*. *Infect Chemother* **2011**, 43, 86. [CrossRef]
- 26. Fernández-Natal, I.; Sáez-Nieto, J.A.; Medina-Pascual, M.J.; Albersmeier, A.; Valdezate, S.; Guerra-Laso, J.M.; Rodríguez, H.; Marrodán, T.; Parras, T.; Tauch, A.; et al. *Dermabacter hominis*: A usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples. *New Microbes New Infect.* **2013**, *1*, 35–40. [CrossRef] [PubMed]
- 27. Schaub, C.; Dräger, S.; Hinic, V.; Bassetti, S.; Frei, R.; Osthoff, M. Relevance of *Dermabacter hominis* isolated from clinical samples, 2012–2016: A retrospective case series. *Diagn. Microbiol. Infect. Dis.* **2020**, *98*, 115118. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.